

EXHIBIT L



Signatera™
Residual disease test (MRD)



JOIN OUR INDUSTRY EXPERT THEATER AT 2021 ASCO® ANNUAL MEETING:

The value of a tumor-informed
approach for early MRD detection*

Join Us!

Learn why a tumor-informed approach using Signatera enables the highest level of sensitivity and specificity required to stratify high risk patients and accurately detect molecular residual disease (MRD).

Go to am.asco.org and click on "Exhibits & Industry Expert Theater" to find Natera's presentation.

DATE

Monday, June 7, 2021
8:30 AM- 9:10 AM (ET)

SPEAKER

Alexey Aleshin, MD, MBA
Vice President,
Medical Affairs, Oncology



*Not an official presentation of the 2021 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO® or Conquer Cancer® The ASCO Foundation. Not CME-accredited.